Trials / Terminated
TerminatedNCT01095809
Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema
Open , Randomized Study About Efficacy, Safety and Tolerability od Repeated Dosis of Intravitreous Bevacizumab in Patients With Uveitic Macular Oedema
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Hospital Clinic of Barcelona · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether intravitreous bevacizumab or intravitreous triamcinolone acetonide are effective and safe in the treatment of uveitic macular oedema
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bevacizumab | 2.5mg at baseline, week 4 and 8. Beyond this initial period if needed reinjection criteria are described in protocol |
| DRUG | triamcinolone acetonide | 2 mg at baseline; frequency every three months if needed. reinjection criteria are described in protocol |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
- First posted
- 2010-03-30
- Last updated
- 2012-03-23
Locations
5 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01095809. Inclusion in this directory is not an endorsement.